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To aim of this study is to analyse the survival rate and prognostic indicators of systemic lupus
erythematosus (SLE) in Pakistani population. A total of 198 patients with SLE diagnosed between
1992 and 2005 were reviewed retrospectively. Clinical features at presentation, subsequent evolving
features, autoantibody profile, damage scores and mortality data were obtained. Prognostic factors
for survival were studied by statistical analysis. Of 198 SLE patients studied, 174 were women and
24 were men. The women to men ratio was 7.2:1. Mean age at presentation was 31 years (range
14–76). Mean duration of symptoms before diagnosis was 2.8 years. Mean duration of follow-up
was 34.21 months (±33.69). Mean disease duration was 15.6 years. At diagnosis, arthritis, malar
rash, oral ulcers and alopecia were the commonest features. During the follow-up, the prevalence of
nephritis, arthritis, neurological and hematological disease increased significantly. About 76%
(n = 151) of the patients had organ damage at the time of data analysis, and renal disease was the
commonest cause. Univariate analysis revealed that renal disease (P = 0.000), seizures (P = 0.048),
pleural involvement (P = 0.019), alopecia (P = 0.000) and discoid lesions (P = 0.005) were predic-
tors for damage. Multivariate model, however, revealed that only renal disease was independent
risk factor for damage (P = 0.002). During the study period, 47 patients (24%) died (five due to
disease-related complications and rest as a result of infections). The 3-, 5-, 10-, 15- and 20-year
survival rates of our cohort were 99, 80, 77, 75 and 75%, respectively. Cox regression analysis
revealed that renal involvement (P = 0.002) and infections (P = 0.004) were independent risk fac-
tors for mortality. The survival of our Pakistani SLE patients was significantly lower compared to
that of the Caucasian series reported in last decade. Nephritis not only contributes to organ damage
but also acts a major determinant for survival. Infection remains the commonest cause of death.
Renal involvement and infections are independent risk factors formortality. Judicious use of immu-
nosuppressive agents is necessary to improve the short-term survival of lupus patients. Lupus
(2009) 18, 848–855.
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Introduction
Systemic lupus erythematosus (SLE) is a multisystem
autoimmune disease that predominantly affects
women of childbearing age. It is also a major cause of
mortality and morbidity in young population.1 The
prognosis of SLE in the Western world has improved
remarkably in the past few decades, from a 5-year
survival rate of only 50% in the 1950s2 to a 10-year
survival rate of nearly 90% in the last decade.3,4
However, poor survival of SLE is still reported in cer-
tain ethnic groups such as Indians,5 BlackCaribbeans6
and Hispanics.6
In the last three decades, we have seen an important
increase in the survival of SLE patients, especially in
those patients with renal involvement. Management
with immunosuppressive drugs, such as intravenous
cyclophosphamide or azathioprine has changed the
prognosis in these patients. These results demonstrate
that our patients with SLE increased their life expec-
tancy but are now faced with new types of morbidity
because of the sequelae related to the disease itself.7
The improvement of SLE survival can be attributed
to a number of factors such as the early diagnosis of
renal disease, better serological monitoring,more judi-
cious use of corticosteroids and cytotoxic agents,
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availability and advancement of renal replacement
therapies, and better management of associated
complications like infection, hyperlipidemia and
hypertension.
Despite the overall improvement in the survival of
patients with SLE, 10–25% of patients still succumb
within 10 years of disease onset.8 Severe organ
involvement related to SLE itself4,9 and infection10
remain the main causes of early mortality. It has
been reported that Asian SLE patients living in the
United States and UK have more serious organ man-
ifestations and higher mortality.11 Whether this is also
related to the poorer socio-economic status of the
Asian-Americans remains to be confirmed. Although
there have been few studies on survival patterns in
Indian and Thai patients with SLE,12,13 data on sur-
vival patterns of SLE is scarce in other Southeast
Asian countries including Pakistan in international
literature. In a study from India, the cumulative per-
centage survival at 1, 5 and 10 years was found to be
89, 77 and 60%, respectively.13 The Markov chain
predicted a life expectancy of 13.9 years. Central ner-
vous system (CNS) and renal involvement were poor
prognostic factors. Proteinuria (>0.5 g/day) caused a
50% reduction in life expectancy but increased disease
activity at onset did not predispose to a poor
outcome.13
In the current study, we, retrospectively, followed a
cohort of SLE patients; however, as the study was
conducted retrospectively, selection bias and incom-
pleteness of records were inevitable.
Patients and methods
The Aga khan University Hospital is a tertiary care
referral center. Case note documentation, assessment
of disease activity, generation of damage scores and
definition of disease flares are standardized and
patients are seen by the same group of nephrologists
and rheumatologists throughout.
Between January 1992 and March 2005, 198
patients were admitted with diagnoses of SLE. While
50% of patients were admitted through emergency
department, approximately 45% were admitted
through out-patient consultant clinics and a small per-
centage (5%) of patients was reffered by different pri-
mary and secondary care units. Majority of patients
fulfilled at least four of the revised American College
of Rheumatology (ACR) criteria for the classification
of SLE.14 The following informations were obtained
from all patients at presentation: age, sex, clinical
presentation and organ involvement, disease activity
scores and autoantibody profile. Patients were
followed up at regular intervals of 6–8 weeks. More
frequent follow-up was arranged for patients who
had severe organ involvement, who had just had a
disease flare or who were receiving intensive immuno-
suppression. Damage scores in each system and mor-
tality data were recorded during the disease course of
our patients. Disease activity was measured by the
SLE disease activity index (SLEDAI).15 SLEDAI
scores were obtained at the time of first presentation
and at subsequent visits. Assessment of organ damage
was made using the Systemic Lupus International
Collaborating Clinics/ACR (SLICC/ACR) index.16
Damage was defined as irreversible impairment that
was present after the diagnosis of SLE and persisted
for more than 6 months irrespective of whether it was
related to disease activity or treatment. For patients
whose SLEwas diagnosed before 1998, damage scores
were obtained retrospectively. After 1998, the damage
index was scored yearly. The total cumulative damage
scores were summated for each patient at the end of
the study.
A total of 42 patients, in this cohort of 198 patients
with SLE, were considered lost-to-follow-up. Postal
and residential addresses of these patients were
obtained frommedical record files and were contacted
and encouraged to return to out-patient clinics for an
evaluation or to answer a questionnaire by telephone.
For patients who died during the follow-up period, the
cumulative damage scores just before their death were
taken for analysis.
Laboratory evaluation
Antinuclear antibodies (ANA) were determined
by indirect immunofluorescence. Anti-dsDNA was
assayed using a standard radio-immunoassay proce-
dure (normal value 0.0–6.0 IU/ml). Anti-extractable
nuclear antigen (ENA) antibodies (Ro, La, nRNP
and Sm) were studied by standard enzyme-linked
immunosorbent assay (ELISA-Euro). Serum C3
was measured by nephelometry (normal range
0.88–2.07 g/l). Lupus anticoagulant was screened by
mixing studies and dilute Russell viper venom test.
Anticardiolipin antibodies (IgG and IgM) were
assayed using a standard ELISA kit (Eliza EURO).
A positive test was defined as a value of >10 IU/ml
on at least two occasions more than 3 months apart.
ANA and anti-ENA were obtained at the time of
diagnosis of SLE and were not routinely repeated.
Anti-dsDNA and serum C3 levels were assayed at
the time of initial visit and during period of suspected
disease-flare up. Anticardiolipin antibodies (IgG,
IgM) and lupus anticoagulant were tested for most
patients during the course of the disease, especially
during periods of disease activity.
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Statistical package for social science (SPSS) version
13.0 was used for data analysis. Results are presented
asmean ± standard deviation for quantitative variables
and number (percentages) for qualitative variables.
Univariate analysis was performed by using indepen-
dent sample t-test to compare the means and differ-
ences in proportion were assessed by using Pearson
Chi-Square test. Logistic regression analysis was used
to identify the independent risk factors for damages.
The probability curves of survival were calculated
according to the Kaplan–Meier method and compared
by the log rank test. Multivariate analysis was per-
formed by using Cox proportional hazard model, to
identify the independent risk factor for poor survival.
All the variables with biologically importantP-value of
<0.25 in univariate analysis were selected for the multi-
variate model building. A P-value of <0.05 (two sided)
was considered as statistically significant.
Results
Between 1992 and 2005, at the Aga Khan University
Hospital, 198 in-patients had SLE listed as a discharge
diagnosis. Of these patients, 174 were women and
24 were men. Of all, 149 patients met the ACR criteria
(4 of the 11 criteria) for the diagnosis of SLE. The
remaining 49 patients fulfilled 3 out of 11 ARA crite-
ria and were diagnosed on basis of high index of sus-
picion for the disease, renal or skin biopsies suggestive
of SLE, positive anti-dsDNA antibody titers and
response to therapy. The mean age at presentation
was 31 years with a range of 14–76 years. Mean
duration of follow-up was 34 months (±33.69).
Mean SLEDAI score at disease presentation was
11.7 ± 0.40 (range 4–33).
Cutaneous manifestations of SLE were relatively
less common in our sample. Malar rash was present
in 60 patients (30%), discoid lupus in 30 (15%),
photosensitivity in 12 patients (6%) and alopecia in
44 patients (22%). About 53% (n = 105) were febrile
at the time of presentation.
There were variable occurrences of renal, CNS,
serosal, hematological and articular involvement.
Approximately 45% of the patients (n = 89)
had renal involvement at presentation. Of these
89 patients, 50% of patients had raised serum Cr. At
the time of presentation (normal 0.8–1.1 mg/dl), 67%
patients had microscopic hematuria, 87% had active
urinary casts, 74% had proteinuria detectable on
urine dipstick, whereas 55% had nephrotic-range pro-
teinuria at presentation. Renal biopsy findings
revealed that 64% of the cases had WHO class IV,
17% had WHO class V, 14% had WHO class III
and 5% had class II histology. Serosal involvement
was noted in 44 patients (22%). Pleural effusion was
seen in 33 patients (17%) and pericardial effusion in
18 patients (9%). Arthritis was present in 76 patients
(38%). Symptomatic arthralgias were noted at some
stage in almost all patients. Regarding hematological
parameters, 28% of patients had thrombocytopenia,
22% had leukopenia and 54% had significant lym-
phopenia. About 5% of the patients presented with
pancytopenia (n = 9). CNS involvement was noted
in 26% of patients (n = 52). Of these 52 patients,
15% presented with frank psychosis and 14% had
seizures at some stage during the course of illness.
About 84% of the patients were ANA-positive
(n = 168), anti-dsDNA test results were positive in
74% of patients (n = 146) and anti-Sm was positive
in 50% of patients. No other antibodies, such as rheu-
matoid factor (RF), anti nuclear cytoplasic antibody
(ANCA) or antiphospholipid antibodies, were found
in clinically significant titers.
The overall mortality was 24% (n = 47). There was
no significant gender difference in the prevalence of
major organ manifestations.
About 76% of our patients had organ damage at
the time of data analysis. While 30% of patients had
a SLICC score of one, 32% had a SLICC score of two
and 38% had SLICC score of 3 or more. Table 1
shows the number of patients with damage in various
systems. The kidneys were the commonest organ
being damaged, followed by the CNS, skin and mus-
culoskeletal systems. The median SLICC score of the
whole cohort was 1 (range 0–5) and for those who had
damage, the median SLICC score was 2 (range 1–5).
Regarding immunosuppressive treatment for our
cohort of patients, 178 (90%) were treated with
oral corticosteroids, 39 (20%) received intravenous
pulse methylprednisolone therapy. Around 52%
of patients initially received a high-dose regimen
Table 1 Proportion of patients with damage in various systems
in our SLE cohort (n = 198)
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(oral prednisone ≥1 mg/kg/day or intravenous pulse
methylprednisolone therapy), which was mainly indi-
cated for renal, CNS and hematological disease. The
cumulative percentages of patients who received aza-
thioprine and cyclophosphamide were 81 (41%) and
27 (14%), respectively.
Twelve patients developed end-stage renal failure
and were dialyzed and two patients received kidney
transplant. All of these dialyzed patients survived.
Figure 1 shows the survival analysis of our cohort of
patients. The 3-, 5- and 10-, 15- and 20-year survival
rates were 99, 80, 77, and 75 and 75%, respectively.
During follow-up, 47 (24%) of our patients died,
7 due to disease-related complications (pulmonary
hemorrhage, cerebrovascular accident, acute myocar-
dial infarction secondary to embolic occlusion of left
anterior descending coronary artery, ischemic enteritis
leading to bowel perforation, lupus cerebritis) and the
rest as a result of infections (nocardial and tuberculo-
sis meningitis in four, disseminated cytomegalovirus
infection in one, disseminated tuberculosis in one,
bronchopneumonia in 6, neutropenic fibril illness in
7 and septicemia with and without disseminated intra-
vascular coagulation in the remaining 21 patients).
Risk factors for survival were studied by both uni-
variate (Kaplan–Meier method and compared by the
log rank test) and multivariate analysis (Cox propor-
tional hazard model), using the prevalence of various
clinical features, demographic data such as age and
sex, autoantibodies and presence of damage as pre-
dictor variables. In univariate model, infections
(P = 0.008), renal disease (P = 0.010) and thrombocy-
topenia (P = 0.037) were associated with poor prog-
nosis (Table 2); however, in multivariate model only
renal involvement (P = 0.002) was found to be an
independent risk factor predicting mortality
(Table 3). Figure 2A–D shows the survival curves of
our patients. Impaired renal function and presence of
organ damage were associated with poor survival.
Discussion
This was a retrospective study of the survival and prog-
nostic indicators of SLE in a Pakistani population. In
the autoantibody profile, percentage of ANA in most
studies15,17,18 approached hundred but we only found
86% of our patients to be ANA positive. Use of differ-
ent laboratory technique and dilution method in 1990s
and different substrate whichmight have been antigen-
ically inadequate is possible reason for low ANA
positivity in this study. Besides, in some patients,
immunosuppression was initiated before ANA testing
which might have influenced ANA results. There was
no difference in the prevalence of other antibodies like
dsDNA as compared to Chinese,19 Caucasians,20
Blacks,16,21,22 Hispanics23 and Indians.24 Compared
to Caucasians, our patients had a higher prevalence
of anticardiolipin antibodies.19 However, this may
not be reliable as only 14% of our patients underwent
anticardiolipin antibody screening.
The overall 5-year survival rate of our SLE
patients was 80%. The survival of our SLE cohort is
less as compared to that of the recently reported Cau-
casian and Asian series.3,4,24 SLE mortality tends to
vary among different geographical areas and ethnic
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Figure 1 Cumulative probability of survival in our cohort of
SLE patients (n = 198).





(%) P value OR (95% CI)
Infections 21.4 78.6 0.008 0.27 (0.1–0.74)
None 7.0 93
Renal involvement 23.5 76.5 0.010 2.75 (1.24–6.07)
None 10 90
Raised creatinine 35 65 0.000 4.7 (2.1–10.5)
Normal creatinine 10 90
Seizures 28.6 71.4 0.05 2.43 (0.96–6.14)
None 14.1 85.9
Thrombocytopenia 28 72 0.037 2.4 (1.03–5.8)
Normal platelets 14 86
Alopecia 25 75 0.07 2.11 (0.93–4.8)
None 13.6 86.4





95.0% CI for OR
Lower Upper
CR ≥ 1.4 0.002 3.2 1.5 6.8
Survival analysis and prognostic indicators of SLE patients
MA Rabbani et al.
851
Lupus
groups. Direct comparison of the survival rates
among different studies is not easy because of the
discrepancies in patient selection and treatment pro-
tocols. Most published survival studies of SLE have
been retrospective, and selection bias and incomplete-
ness of medical records are major flaws. Moreover,
the proportion of patients with severe organ manifes-
tations included in different series as a result of
referral pattern may also influence the survival
rates. Prospective studies are, therefore, necessary.
However, as with many other diseases, socioeconomic
status (SES) is an important risk factor for progression
of lupus, independent of race/ethnicity.25,26We believe
that our population has an elevated risk of progression
similar to African-Americans and Hispanics and
given the results of multivariate analyses, much of
the poorer prognosis of our patients may be due to
socio-economic rather than biological or genetic
factors. Indeed, the relative importance of genetic
factors may be amplified by environmental factors
that are associated with poverty. We believe that
social and economic causes of inequity across income
and race/ethnicity should be aggressively investigated
and studies that aim to find putative major genes or
haplotypes to explain race/ethnic disparities should
consider SES. Patients with SLE have an approxi-
mately fivefold increased risk of mortality compared
with the general population.27 Many studies have
described the causes of death of SLE patients.28,29
Death occurs both early and late in the course of
disease and follows a bimodal pattern.29 Early mortal-
ity of SLE is often due to complications related to the
active SLE process itself and infection, while vascular
events and end organ failure unrelated to active SLE
contribute to latemortality.4 Themain causes of death
in our patient cohort were infection and active SLE
with severe organ involvement, which are consistent
with those reported in other series.
A number of lupus- and non–lupus related factors
have been described in association with the prognosis
of SLE.21 Major organ manifestations, particularly
CNS and renal diseases, have long been identified as
markers of poor prognosis.30 Patients who die of
active SLE are more likely to have CNS disease.29





























































































P-value = 0.003 
P-value = 0.497 
P-value = 0.115 
Figure 2 (A) Probability of survival in SLE patients with and without renal disease. (B) Probability of survival in SLE patients who
were and were not initially treated with high-dose corticosteroid. (C) Probability of survival in SLE patients with and without
thrombocytopenia. (D) Probability of survival in SLE patients with and without damage.
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Organic brain syndrome was reported to be a poor
prognostic indicator for survival in an early study by
Esters and Christian.30 Moreover, seizure was found
to be associated with a poorer overall survival of SLE
in a study by Ward, et al.8 Lupus nephritis, especially
diffuse proliferative glomerulonephritis, carries a poor
prognosis in most studies.8,18,31–33 Elevated serum cre-
atinine, reduced creatinine clearance and progressive
WHO class of lupus nephritis were associated with
decreased survival. Our data demonstrated CNS
(seizures) and renal disease to be significant predictors
for survival in our cohort. All our six patients who
developed end-stage renal failure survived on dialysis,
indicating availability of improved renal replacement
therapies. Hematological manifestations, in particular
thrombocytopenia, have also been cited as adverse
factor for poor outcome in SLE.18,33 However, we
could not find any relationship between low platelet
count and outcome (Figure 2C). Apart from two
patients, one died of pulmonary hemorrhage, which
was thought to be caused by fulminant vasculitis,
and another one who died of massive gastrointestinal
(GI) bleed, no other patient suffered from significant
morbidity and mortality secondary to bleeding com-
plications. WHO class IV was associated with poor
prognosis, which in turn was the main indication for
heavy immunosuppressive therapy at the time of diag-
nosis of SLE.
Treatment is a pivoting factor affecting survival of
SLE patients. Judicious use of steroid and cytotoxic
agents such as cyclophosphamide and azathioprine to
achieve a better control of disease activity is one of
the well-recognized reasons for the improvement in
survival of SLE patients in recent years. However,
heavy immunosuppression, such as mega doses of ste-
roid, may adversely affect short-term survival of SLE
because of the risk of infection. Although in the
current study, we have shown that initial treatment
with high-dose oral prednisone or intravenous
methylprednisolone bolus is not a significant risk
factor for damage andmortality in both the univariate
and multivariate models (Figure 2B), high-dose
steroid treatment is, however, associated with a
number of side-effects such as susceptibility to oppor-
tunistic infection, avascular bone necrosis, cataract,
glaucoma, secondary diabetes, osteoporosis and its
complications, which contributed significantly tomor-
bidity in our cohort. Our result is in keeping with that
from Massado, et al.33 who also demonstrated that
over immunosuppression for the treatment of patients
with more severe disease was associated with higher
mortality in their Chilean SLE patients. Given the
strong relationship between heavy immunosuppres-
sion and bone marrow suppression and serious
opportunistic infections leading to high mortality
rates, efforts should assiduously be made to avoid
unnecessary over-immunosuppressive treatment in
patients with SLE.
Race appears to play a role in disease prognosis in
SLE, although it is difficult to separate the effect of
race from socio-economic status. Non-White popula-
tions residing in Hawaii, which were exclusively
Asians, were found to have more serious SLE and
mortality than Whites.34 This may possibly be related
to the lower socio-economic condition of the Asian-
Americans. Black patients, when compared with
Whites, also have more severe organ manifestations
and poorer survival.1,35 However, a multicenter
study of a large cohort of SLE patients demonstrated
that apparent racial differences in survival could be
accounted for by differences in medical insurance sta-
tus between Blacks and Whites.32 Moreover, Ward,
et al.36 also showed that socio-economic status,
instead of race, is a strong indicator for survival.
The age at onset of SLE has also been reported as a
significant predictor for survival, although currently
available data are conflicting. In the multicenter
study by Ginzler, et al.32 better 1- and 5-year survival
rates were demonstrated in older SLE patients. More-
over, pediatric-onset SLE patients have been associ-
ated with a worse prognosis.37 However, a study
comparing the outcome of adult- and childhood-
onset SLE patients did not reveal any difference in the
5-year survival rates.38 On the contrary, two recent
studies showed that increasing age is a risk factor for
death.18,36 This is in contradiction to the common
observation that late-onset SLE often runs a more
benign disease course.39 The effect of gender on SLE
survival is also controversial. Male SLE patients were
reported to have more severe renal disease and
reduced survival40 when compared with their female
counterparts. However, other studies failed to show a
gender difference in damage and mortality rates of
SLE.18,41,42 We were unable to demonstrate a contri-
bution of either age at onset or sex to survival in our
patients (P = 0.2126). No gender differences in major
organ manifestations, damage scores (P = 0.84) and
survival rates (P = 0.2126) could be demonstrated.
There is still little information in the literature
regarding the relationship between damage and sur-
vival in SLE patients. In a retrospective study by Stoll,
et al.43 that involved an inception cohort of 80 SLE
patients, it was reported that the mean renal and pul-
monary scores at 1 year after the diagnosis of SLE
predicted for renal failure and mortality, respectively,
within 10 years. Because of the problem of obtaining
reliable damage scores retrospectively for some of our
patients at 1 year post-diagnosis of SLE and the small
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number of patients who developed renal failure
(n = 10) within a relatively short period of follow-up,
statistical analysis of our data regarding damage
scores at 1 year and subsequent outcome was not fea-
sible. However, we were able to demonstrate that the
cumulative SLICC score was a predictor for survival
in both the univariate and multivariate models
(Figure 2D).
Renal damage was the commonest form of organ
damage in our cohort. Renal disease was not only a
predictor for damage but was also an independent
risk factor for survival (P = 0.002). Of the 89 (45%)
patients with renal disease in our cohort, 75 (84%)
had renal damage. This suggests that most patients
with nephritis did not respond well to treatment, and
it is, therefore, because of this poor therapeutic
response that renal disease was shown to be a strong
predictor for renal damage in logistic regression anal-
ysis (P = 0.002).
In summary, this is the first study of the survival of
Pakistani SLE patients ever reported in the English
literature. The long-term survival of our patients is
comparable to that of the Caucasian series in the
1990s.44 Renal disease not only contributes to organ
damage but is also a strong determinant for survival.
Infection remains the main cause of death in this
cohort (P = 0.004). Seizures, alopecia and thrombocy-
topenia are independent risk factors for mortality in
the univariate model. Although, lupus survival has
significantly improved in the recent decade, further
improvement should be pursued. Judicious use of
corticosteroids and cytotoxic agents to prevent
over-immunosuppression, particularly in patients
with serious disease manifestations, is essential.
Continuous follow-up of our cohort of SLE patients
is necessary to accrue data on long-term survival of
the disease.
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